Oracle (ORCL) stock turns lower after early rally as 2026 begins; rates, AI spending in focus
2 January 2026
1 min read

Oracle (ORCL) stock turns lower after early rally as 2026 begins; rates, AI spending in focus

NEW YORK, January 2, 2026, 10:41 ET — Regular session

Oracle shares edged down on Friday, slipping 0.2% to $194.48 in morning trading after opening near $198 and briefly touching $198.60. The stock has traded as low as $194.32.

The dip came even as Wall Street opened the first trading day of 2026 with gains. At the opening bell, the S&P 500 rose 0.48% and the Nasdaq Composite gained 1.03%. 1

Investors are watching whether a busy January calendar resets the outlook for U.S. interest rates, a key driver for tech valuations. The U.S. jobs report due Jan. 9 and the consumer price index on Jan. 13 are in focus, and Fed funds futures — contracts that reflect bets on the policy path — show little chance of a cut at the late-January meeting and roughly 50% odds of a quarter-point move in March. “The market is looking for direction,” said Matthew Maley, chief market strategist at Miller Tabak. 2

For Oracle, that macro backdrop matters because the stock has been swinging with scrutiny over the company’s heavy investment cycle. In December, Oracle forecast profit and revenue for the current quarter below analyst estimates and said fiscal 2026 spending would rise by $15 billion compared with earlier plans. 3

That spending — capital expenditures, or capex — is money for long-lived assets such as data centers and hardware. Oracle has been pushing deeper into cloud infrastructure to support AI workloads and enterprise demand.

In its most recent quarterly update, Oracle said remaining performance obligations — contracted revenue not yet recognized — jumped 438% from a year earlier to $523 billion. Cloud revenue rose 34% to $8.0 billion. 4

Investors also have a near-term company calendar item next week. Oracle declared a quarterly cash dividend of $0.50 per share payable Jan. 23 to shareholders of record as of Jan. 9, a regulatory filing showed. 5

In Friday’s tape, Oracle’s retreat from an early pop highlighted how quickly momentum can fade when rate sensitivity meets capex anxiety. Traders have been treating the $200 level as a round-number marker after the stock’s sharp moves in December.

Oracle’s competitive backdrop remains intense. It is chasing cloud infrastructure workloads against Amazon’s AWS and Microsoft’s Azure, with AI-related capacity and pricing a central theme across the sector.

What investors will be listening for next is whether Oracle’s cloud backlog converts into revenue fast enough to justify the buildout, and whether management signals more predictability on spending after last month’s reset.

The next scheduled company update is Oracle’s fiscal third-quarter earnings report in mid-March, according to its investor relations FAQ. 6

Until then, Oracle stock is likely to trade on a mix of macro rate signals and any new read-throughs on enterprise cloud demand, with investors weighing growth against the cost of building it.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
AMD stock jumps to start 2026 as MI450 AI chips and Helios racks draw fresh attention
Previous Story

AMD stock jumps to start 2026 as MI450 AI chips and Helios racks draw fresh attention

IBM’s 2026 quantum milestone puts IonQ and Nvidia back on investors’ radar
Next Story

IBM’s 2026 quantum milestone puts IonQ and Nvidia back on investors’ radar

Go toTop